Press release·08/15/2026 01:00:50

Overview of LeonaBio’s Financial Performance

LeonaBio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). The company has two lead drug candidates, lasofoxifene and brelgometon, which are currently in clinical development.

For the six months ended June 30, 2026, LeonaBio reported a net loss of $52.0 million, compared to a net loss of $16.1 million for the same period in 2025. This significant increase in net loss was primarily driven by a $16.0 million rise in research and development expenses and a $16.3 million change in the fair value of the Sermonix pre-funded warrant.

Revenue and Profit Trends

LeonaBio is a clinical-stage company and has not generated any revenue from product sales to date. The company’s operations have been funded primarily through the sale of equity securities, including its initial public offering, a follow-on public offering, and a private placement in December 2025 that raised approximately $90 million in gross proceeds.

The company’s net losses have increased over time as it has advanced its drug candidates through clinical development. Research and development expenses, which include the costs of conducting preclinical studies and clinical trials, as well as manufacturing activities, have been the primary driver of these losses. For the six months ended June 30, 2026, research and development expenses totaled $24.0 million, compared to $8.0 million for the same period in 2025.

The significant increase in research and development expenses was largely due to the advancement of the company’s lead program, lasofoxifene, for the treatment of metastatic breast cancer with ESR1 mutations. Costs related to the ongoing ELAINE-3 registrational Phase 3 trial for lasofoxifene, including contract research organization, clinical site, and manufacturing expenses, increased by $17.7 million compared to the prior year period.

In addition, LeonaBio recorded a $16.3 million change in the fair value of the Sermonix pre-funded warrant, which was issued in connection with the December 2025 private placement. This non-cash charge further contributed to the company’s net loss for the six-month period.

Strengths and Weaknesses

Strengths:

• Promising late-stage asset in lasofoxifene for the treatment of ESR1-mutated metastatic breast cancer
• Complementary pipeline asset in brelgometon for the potential treatment of ALS
• Experienced management team with expertise in clinical development and commercialization
• Successful track record of raising capital to fund operations, including the recent $90 million private placement

Weaknesses:

• Reliance on external contract manufacturing organizations and clinical research organizations, which could introduce risks and delays
• No approved products or revenue-generating operations, resulting in continued operating losses
• Significant cash burn rate, with current cash and investments potentially insufficient to fund operations for the next 12 months
• Potential challenges in obtaining regulatory approval and commercializing drug candidates, even if clinical trials are successful

Outlook and Future Prospects

LeonaBio’s future prospects are closely tied to the successful development and potential commercialization of its two lead drug candidates, lasofoxifene and brelgometon.

The company’s primary focus is on advancing the ELAINE-3 registrational Phase 3 trial for lasofoxifene in patients with ESR1-mutated metastatic breast cancer. LeonaBio has enrolled 495 of the approximately 600 planned participants in this trial and expects to complete enrollment in the fourth quarter of 2026, with topline data anticipated in the second half of 2027.

If the ELAINE-3 trial is successful and lasofoxifene receives regulatory approval, the drug could represent a significant commercial opportunity for LeonaBio, as current treatment options for ESR1-mutated metastatic breast cancer are limited.

Regarding brelgometon, the company plans to initiate a Phase 2 proof-of-concept clinical trial for the treatment of ALS following the completion of enrollment in the ELAINE-3 trial. ALS is a devastating neurodegenerative disease with few effective treatment options, and brelgometon’s novel mechanism of action targeting the neurotrophic HGF system could potentially offer a new approach to address this unmet need.

However, LeonaBio faces several challenges that could impact its future prospects. The company’s reliance on external partners for manufacturing and clinical development introduces risks and potential delays. Additionally, the company’s significant cash burn rate and the potential need for additional funding to support its operations and clinical programs raise concerns about its ability to continue as a going concern in the near term.

Overall, LeonaBio’s financial performance reflects the typical challenges faced by a clinical-stage biopharmaceutical company. The company’s success will ultimately depend on the successful development and commercialization of its drug candidates, particularly lasofoxifene, as well as its ability to secure additional funding to support its ongoing operations and future growth.